Gordon Guyatt's Confession: What the Father of Evidence-Based Medicine Didn't Read (#36)
Gordon Guyatt coined evidence-based medicine in 1991 — the very framework European health authorities now use to evaluate paediatric gender interventions. His systematic reviews returned a verdict of low-quality evidence, echoing conclusions already reached in Sweden, Finland, and the UK. Yet in this interview he reveals he signed a statement endorsing gender-affirming care without reading it, and admits he is 'a total non-expert' in the field. For clinicians, regulators, and policymakers across the continent, his confession raises questions that cannot simply be dismissed.
Gordon Guyatt did not merely contribute to medical science — he gave it the language it uses to judge itself. As professor at McMaster University, he coined 'evidence-based medicine' in 1991 and built the hierarchy of evidence that governs clinical guidelines from Helsinki to Lisbon. When health authorities in Sweden, Finland, or EU member states weigh whether an intervention is safe and effective, they reach for a framework Guyatt constructed. That is what makes his conversation with Beyond Gender so significant — and so uncomfortable. His research group conducted systematic reviews of paediatric gender medicine and found the evidence consistently low in quality. That conclusion echoed what Swedish, Finnish, and British health authorities had already determined through their own national reviews, which prompted each to restrict or substantially limit such interventions for minors. Guyatt's work appeared to offer independent, methodologically rigorous confirmation — from the very person who invented the method being applied. What this episode exposes is the gap between that scientific conclusion and Guyatt's public positioning. When twenty American states cited his reviews to justify legislative restrictions, he condemned this as 'egregious, unconscionable misuse' of his work. Yet during the interview he reveals that he signed a statement endorsing 'medically necessary care for gender diverse youth' without reading it carefully. 'That was not my paragraph, and I didn't read carefully enough,' he says. Asked to account for it: 'I was a dope. Okay. I'm sometimes a dope.' For European clinicians and policymakers who have been navigating exactly this tension between evidence and advocacy, the admission is not easily set aside. Guyatt repeatedly describes himself as 'a total non-expert' in paediatric gender medicine. When asked whether adolescents can give meaningful informed consent to interventions affecting their fertility — a question central to ongoing regulatory debates in the Netherlands, France, and Germany — he deflects to analogies from geriatric care. A paediatric endocrinologist's remark that discussing fertility with a fourteen-year-old is 'like talking to a blank wall' he dismisses as a single anecdote. Yet his own confidence that a treatable subpopulation exists, he concedes, rests on impressions from conversations rather than systematic evidence. The parallel he is invited to consider — and resists — involves bone marrow transplants for breast cancer, a case in which patient advocacy drove widespread adoption of a treatment that ultimately proved harmful to women. It is not an obscure reference; it is a canonical example within the discipline of evidence-based medicine itself. That he finds the comparison manipulative says something, as does the fact that he says so. For European listeners, the episode functions as an anatomy lesson. Evidence-based medicine was conceived precisely as a check on enthusiasm — on the human tendency of clinicians and researchers to believe what they want to believe before the data are in. What emerges from this interview is that its founder has not been immune to that tendency either. Across the continent, health institutions are making decisions about what they owe young people with gender distress. Guyatt's confession is a reminder of how much those decisions depend on who is reading the evidence, and how carefully.
